Adaptive Biotechnologies Corporation
US ˙ NasdaqGS ˙ US00650F1093

SecurityADPT / Adaptive Biotechnologies Corporation
InstitutionSavant Capital, LLC
Latest Disclosed Ownership16,651 shares
Latest Disclosed Value $ 231,116
Savant Capital, LLC reports 0.93% increase in ownership of ADPT / Adaptive Biotechnologies Corporation

On May 4, 2026 - Savant Capital, LLC filed a 13F-HR form disclosing ownership of 16,651 shares of Adaptive Biotechnologies Corporation (US:ADPT) valued at $231,116 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 10, 2026 disclosing 16,497 shares of Adaptive Biotechnologies Corporation. This represents a change in shares of 0.93% during the quarter. The current value of the position is $281,402 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date
Effective
Date
Form Security Class ID Avg Price
Paid (Est)
Reported
Shares
ΔShares ΔShares
(%)
Reported
Value
(x1000)
ΔValue
(%)
Alloc
(%)
ΔAlloc ΔAlloc (%) Cost Basis
(x1000)
Unrealized
Gain/Loss
(x1000)
2026-05-04 2026-03-31 13F ADAPTIVE BIOTECHNOLOGIES COR COM 00650F109 16,651 154 0.93 231 -13.48 0.0011
2026-02-10 2025-12-31 13F ADAPTIVE BIOTECHNOLOGIES COR COM 00650F109 16,497 4 0.02 268 8.54 0.0015
2026-03-04 2025-09-30 13F/A-1 ADAPTIVE BIOTECHNOLOGIES COR COM 00650F109 16,493 0 0.00 247 28.13 0.0015
2025-11-05 2025-09-30 13F ADAPTIVE BIOTECHNOLOGIES COR COM 00650F109 39,762 97 595 0.0031
2026-03-04 2025-06-30 13F/A-1 ADAPTIVE BIOTECHNOLOGIES COR COM 00650F109 16,493 0 0.00 192 57.38 0.0014
2025-08-06 2025-06-30 13F ADAPTIVE BIOTECHNOLOGIES COR COM 00650F109 39,665 5,305 462 0.0029
2026-03-04 2025-03-31 13F/A-1 ADAPTIVE BIOTECHNOLOGIES COR COM 00650F109 16,493 -17,728 -51.80 123 -40.49 0.0010
2025-05-08 2025-03-31 13F ADAPTIVE BIOTECHNOLOGIES COR COM 00650F109 34,360 139 255 0.0019
2025-01-29 2024-12-31 13F ADAPTIVE BIOTECHNOLOGIES COR COM 00650F109 34,221 1 0.00 205 17.14 0.0016
2024-11-04 2024-09-30 13F ADAPTIVE BIOTECHNOLOGIES COR COM 00650F109 34,220 0 0.00 175 42.28 0.0015
2024-08-05 2024-06-30 13F ADAPTIVE BIOTECHNOLOGIES COR COM 00650F109 34,220 17,594 105.82 124 132.08 0.0012
2024-05-06 2024-03-31 13F ADAPTIVE BIOTECHNOLOGIES COR COM 00650F109 16,626 133 0.81 53 -33.75 0.0006
2024-02-05 2023-12-31 13F ADAPTIVE BIOTECHNOLOGIES COR COM 00650F109 16,493 -1,500 -8.34 81 -18.37 0.0010
2023-11-07 2023-09-30 13F ADAPTIVE BIOTECHNOLOGIES COR COM 00650F109 17,993 17,993 98 0.0015
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.